{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Childhood+Neoplasm&page=77", "query": { "condition": "Malignant Childhood Neoplasm", "page": 77 }, "page_size": 10 }, "pagination": { "page": 77, "page_size": 10, "total_count": 2047, "total_pages": 205, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Childhood+Neoplasm&page=78&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Childhood+Neoplasm&page=76&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T18:06:02.375Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01516684", "title": "Local Anesthetic Cream in Younger Patients Undergoing Lumbar Punctures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "placebo administration", "type": "DRUG" }, { "name": "EMLA", "type": "DRUG" }, { "name": "propofol", "type": "DRUG" }, { "name": "fentanyl citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "22 Years", "sex": "ALL", "summary": "Up to 22 Years" }, "enrollment_count": 33, "start_date": "2012-05-14", "completion_date": "2018-06-26", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01516684" }, { "nct_id": "NCT02464098", "title": "Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diarrhea" ], "interventions": [], "intervention_types": [], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "18 Years", "sex": "ALL", "summary": "Up to 18 Years" }, "enrollment_count": 200, "start_date": "2015-11-19", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02464098" }, { "nct_id": "NCT07658677", "title": "Cannabis Gummy for the Improvement of Sleep and Quality of Life in Patients With Cancer, Pillow Trial", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Actigraphy", "type": "OTHER" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ecological Momentary Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Single Agent Therapy", "type": "DRUG" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG" ], "sponsor": "Theodore Brasky PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2027-01-15", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07658677" }, { "nct_id": "NCT02229136", "title": "Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Stomatitis", "Oral Mucositis", "Neoplasm of the Breast", "Malignant Tumor of Breast" ], "interventions": [ { "name": "Miracle Mouthwash Plus Hydrocortisone", "type": "DRUG" }, { "name": "Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 104, "start_date": "2014-09-04", "completion_date": "2022-11", "has_results": false, "last_update_posted_date": "2022-12-01", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 1, "location_summary": "US, Texas", "locations": [ { "city": "US", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02229136" }, { "nct_id": "NCT03739372", "title": "Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioma", "Glioma of Brain", "Cancer", "Pediatric Cancer", "Pediatric Brain Tumor", "Astrocytoma", "Glioblastoma", "Hemispheric" ], "interventions": [ { "name": "Specialized tumor board recommendation", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 44, "start_date": "2018-11-28", "completion_date": "2026-05-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 12, "location_summary": "San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739372" }, { "nct_id": "NCT05039801", "title": "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Endometrial Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Clear Cell Adenocarcinoma", "Chondrosarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Refractory Endometrial Carcinoma", "Refractory Head and Neck Squamous Cell Carcinoma", "Refractory Melanoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Stage III Ovarian Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Glutaminase-1 Inhibitor IACS-6274", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-09-30", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039801" }, { "nct_id": "NCT05150028", "title": "A Virtual Intervention to Improve Medication Adherence in Pediatric Cancer: MedSupport", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Medication Adherence" ], "interventions": [ { "name": "Patient participation", "type": "BEHAVIORAL" }, { "name": "Clinician barrier reports", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 16, "start_date": "2023-04-11", "completion_date": "2024-06-06", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05150028" }, { "nct_id": "NCT06251544", "title": "TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Tumor, Breast", "Breast Tumor", "Malignant Neoplasm of Breast", "Mammary Cancer", "Mammary Neoplasm", "Mammary Neoplasms, Human", "Neoplasm, Breast" ], "interventions": [ { "name": "HTR2 T Cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 27, "start_date": "2026-08-03", "completion_date": "2044-01", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06251544" }, { "nct_id": "NCT06040970", "title": "Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer", "Malignant Neoplasm of Uterus" ], "interventions": [ { "name": "Sacituzumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 54, "start_date": "2024-10-28", "completion_date": "2032-07-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06040970" }, { "nct_id": "NCT01250470", "title": "Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Giant Cell Glioblastoma", "Glioblastoma", "Gliosarcoma", "Mixed Glioma", "Recurrent Brain Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Montanide ISA-51/Survivin Peptide Vaccine", "type": "DRUG" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2012-09-05", "completion_date": "2014-05-29", "has_results": false, "last_update_posted_date": "2017-02-27", "last_synced_at": "2026-11-04T18:06:02.375Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01250470" } ] }